Daniel Christoph, Vogelbacher Regina, Stief Andrea, Grigo Christina, Hugo Christian
Department of Pathology, Nephropathology, University of Erlangen-Nuremberg, Erlangen, Germany.
Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany.
PLoS One. 2013 Dec 23;8(12):e83846. doi: 10.1371/journal.pone.0083846. eCollection 2013.
We recently identified Thrombospondin-2 (TSP-2) as a regulator of matrix remodelling and inflammation in experimental kidney disease by using TSP-2 null mice and successfully proved TSP-2 overexpression as a therapeutic concept in a short term glomerulonephritis model in the rat. In this current study, we investigated if long-term TSP-2 overexpression is also capable to ameliorate the progression of chronic kidney disease in the setting of the chronic allograft nephropathy F344-Lewis model in the rat. Two weeks after renal transplantation, two rat thigh muscles were transfected once only with either a TSP-2 overexpressing plasmid (n = 8) or a luciferase-expressing plasmid as control (n = 8). Rats were monitored for renal function, histological changes and gene expression in the graft for up to 30 weeks after transplantation. Unexpectedly, only in the TSP-2 treated group 2 rats died before the end of the experiment and renal function tended to be worsened in the TSP-2 group compared to the luciferase-treated controls. In addition, glomerular sclerosis and tubular interstitial injury as well as cortical fibronectin deposition was significantly increased in the TSP-2 treated kidneys despite reduced TGF-β activation and marked anti-inflammatory (macrophages, T-cells and B-cells) effects in this group. Long-term TSP-2 therapy impaired repair of renal endothelium, as demonstrated by significant higher glomerular and peritubular endothelial rarefaction and reduced endothelial cell proliferation in the transplanted kidneys from TSP-2 treated rats compared to controls. This TSP-2 effect was associated with decreased levels of renal VEGF but not VEGF1 receptor. In conclusion, despite its anti-inflammatory and TGF-β activation blocking effects, TSP-2 gene therapy did not ameliorate but rather worsened experimental chronic allograft nephropathy most likely via its anti-angiogenic properties on the renal microvasculature.
我们最近通过使用血小板反应蛋白-2(TSP-2)基因敲除小鼠,确定TSP-2为实验性肾脏疾病中基质重塑和炎症的调节因子,并在大鼠短期肾小球肾炎模型中成功证明TSP-2过表达是一种治疗理念。在本研究中,我们调查了在大鼠慢性移植肾病F344-Lewis模型中,长期TSP-2过表达是否也能够改善慢性肾脏病的进展。肾移植两周后,仅用TSP-2过表达质粒(n = 8)或荧光素酶表达质粒作为对照(n = 8)对两只大鼠大腿肌肉进行一次转染。在移植后长达30周的时间内,监测大鼠的肾功能、组织学变化以及移植物中的基因表达。出乎意料的是,仅在TSP-2治疗组中,有2只大鼠在实验结束前死亡,并且与荧光素酶治疗的对照组相比,TSP-2组的肾功能有恶化趋势。此外,尽管该组中TGF-β激活减少且具有显著的抗炎(巨噬细胞、T细胞和B细胞)作用,但TSP-2治疗的肾脏中肾小球硬化、肾小管间质损伤以及皮质纤维连接蛋白沉积显著增加。长期TSP-2治疗损害了肾内皮的修复,与对照组相比,TSP-2治疗的大鼠移植肾中肾小球和肾小管周围内皮稀疏显著增加,内皮细胞增殖减少,证明了这一点。这种TSP-2效应与肾VEGF水平降低有关,但与VEGF1受体无关。总之,尽管TSP-2具有抗炎和阻断TGF-β激活的作用,但其基因治疗并未改善反而恶化了实验性慢性移植肾病,这很可能是由于其对肾微血管的抗血管生成特性所致。